

> Myeloid neoplasm overview (Blood 2016;127:2391)


# MYELODYSPLASTIC SYNDROMES (MDS)

Myeloid neoplasm overview (_Blood_ 2016;127:2391)

• Categories based on 臨床表現, morphology, immunophenotyping, and genetics

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>WHO 2016 Classification of Myeloid Neoplasms &amp; Acute Leukemia</b></p></td></tr><tr><td><p>Acute myeloid leukemia</p></td><td><p>Clonal myeloid stem cell (SC) disorder with ≥20% blasts</p></td></tr><tr><td><p>Myelodysplastic syndromes</p></td><td><p>Dysplastic clonal myeloid SC disorder → cytopenias; &lt;20% blasts, risk of leukemic transformation</p></td></tr><tr><td><p>Myeloproliferative neoplasms</p></td><td><p>Nondysplastic multipotent myeloid SC clonal expansion</p></td></tr><tr><td><p>MDS/MPN neoplasms</p></td><td><p>Features of MDS &amp; MPN (eg, CMML, atypical CML)</p></td></tr><tr><td><p>Myeloid/lymphoid malig. with eos &amp; rearrangements of <i>PDGFR</i> or <i>FGFR1</i> or with <i>PCM1-JAK2</i></p></td><td><p>May be responsive to TKI therapy (eg, imatinib) for <i>PDGFR</i> rearrangement</p></td></tr><tr><td><p>Mastocytosis</p></td><td><p>Systemic disease, assoc with <i>KIT</i> mutations</p></td></tr><tr><td><p>Myeloid neoplasms with germ line predisposition</p></td><td><p>MDS, MDS/MPN, acute leukemias in background of predisposing germline mutations</p></td></tr></tbody></table>

Myelodysplastic syndromes (MDS) overview (_Lancet_ 2014;383:2239)

• Acquired clonal stem cell disorder → ineffective hematopoiesis → **cytopenias**, **dysmorphic blood cells and precursors**, variable risk of **leukemic transformation**

• 流行病學: 20–30,000 cases/y; median age ~70 y; male predominance (1.8×)

• **Idiopathic** or 2° to chemo with **alkylating agents;** ↑ risk with radiation, benzene

• 臨床表現: **anemia** (85%), neutropenia (50%), thrombocytopenia (40–65%)

• Diagnosis: dysplasia (usually multilineage) in peripheral smear (oval macrocytes, **pseudo-Pelger-Huët anomaly**) and bone marrow (≥10% dysplasia with blasts ± RS)

• Both **cytogenetic** \[eg, del(5q), mono 7, del(7q), trisomy 8, del(20q)\] and **molecular** 異常 (**TP53**, EZH2, ETV6, RUNX1, ASXL1, SF3B1, DNMT3A) may carry prognostic signif

• Prior to dx MDS: exclude AML (≥20% blasts) and CMML (monos >1 × 109/L); 排除 2° BM Δs (defic. of B12, folate, copper); viral infx (eg, HIV); chemo; EtOH; lead, arsenic exposures

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>WHO 2016 Classification Systems for MDS</b> <span>(</span><span><i>Blood</i></span> <span>20</span><span>1</span><span>6;</span><span>1</span><span>27:239</span><span>1</span><span>)</span></p></td></tr><tr><td><p><b>Classification</b></p></td><td><p><b>WHO 2008</b></p></td><td><p><b>Features</b></p></td></tr><tr><td><p>MDS with single lineage dysplasia (MDS-SLD)</p></td><td><p>RCUD</p><p>(RA/RN/RT)</p></td><td><p>1 dysplastic lineage, 1–2 cytopenias, &lt;15% RS<a id="st7"></a><a href="text/part0010_split_007.html#sst7">*</a>, &lt;5% BM/&lt;1% PB blasts, no Auer rods</p></td></tr><tr><td><p>MDS with multilineage dysplasia (MDS-MLD)</p></td><td><p>RCMD</p></td><td><p>2–3 dysplastic lineages, 1–3 cytopenias, &lt;15% RS<a href="text/part0010_split_007.html#sst7">*</a>, &lt;5% BM/&lt;1% PB blasts, no Auer rods</p></td></tr><tr><td><p>MDS with ring sideroblast (MDS-RS)</p></td><td><p>RARS</p></td><td><p>≥15% RS or ≥5% RS if <i>SF3B1</i> mut. is present, &lt;5% BM/&lt;1% PB blasts, no Auer rods</p></td></tr><tr><td><p>MDS with isolated del(5q)</p></td><td><p>Del(5q)</p></td><td><p>Del(5q) alone or with 1 異常 except –7 or del(7q)</p></td></tr><tr><td><p>MDS with excess blasts (MDS-EB)</p></td><td><p>RAEB-1</p><p>RAEB-2</p></td><td><p>EB-1: 5–9% BM/2–4% PB blasts, no Auer rods</p><p>EB-2: 10–19% BM/5–19% PB blasts or Auer rods</p></td></tr><tr><td><p>MDS, unclassifiable (MDS-U)</p></td><td><p>MDS-U</p></td><td><p>w/ 1% PB blasts, single lineage dysplasia &amp; pancytopenia, or defining cytogenetic alteration</p></td></tr></tbody></table>

Certain cytogenetics \[eg, t(15;17), t(8;21), inv16, t(16;16), or MLL rearrangement\] classified as AML, regardless of BM blast count. RS, ring sideroblast; BM, bone marrow; PB, peripheral blood. [\*](text/part0010_split_007.html#st7) <5% RS if _SF3B1_ mutation.

• Rx (_Am J Hematol_ 2012;87:692): intensity based on IPSS-R (qv), age, performance status (PS)

Poor PS, any risk → supportive care (transfusions, G-CSF, Epo, TPO-mimetic, 抗生素 prn)

Low/intermediate risk → Epo (if Epo level <500); lenalidomide (esp. for 5q syndrome; _Blood_ 2011;118:3765); DNA hypomethylating agents (azacitidine or decitabine)

Intermediate/high risk (>4.5 on IPSS-4) → **allogeneic HSCT** if medically fit, otherwise **DNA hypomethylating agents** (decitabine or azacitidine; _Lancet Oncol_ 2009;10:223)

Hypoplastic MDS (rare) → consider **immunosuppression** (CsA, ATG, pred), HSCT

• Prognosis: _TP53_, _RAS_, _JAK2_ mutations (_NEJM_ 2017; 376:536) & IPSS-R correlate with survival

![](https://i.imgur.com/83yVaae.jpg)
